PDT Partners LLC bought a new position in Calithera Biosciences, Inc. (NASDAQ:CALA) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 18,690 shares of the biotechnology company’s stock, valued at approximately $278,000. PDT Partners LLC owned approximately 0.05% of Calithera Biosciences at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently modified their holdings of the company. Legal & General Group Plc acquired a new position in shares of Calithera Biosciences in the 2nd quarter worth approximately $120,000. Raymond James Financial Services Advisors Inc. acquired a new position in Calithera Biosciences during the 1st quarter valued at approximately $117,000. Hillsdale Investment Management Inc. acquired a new position in Calithera Biosciences during the 2nd quarter valued at approximately $166,000. Nationwide Fund Advisors acquired a new position in Calithera Biosciences during the 1st quarter valued at approximately $131,000. Finally, KCG Holdings Inc. acquired a new position in Calithera Biosciences during the 1st quarter valued at approximately $144,000. Institutional investors own 71.88% of the company’s stock.
Calithera Biosciences, Inc. (NASDAQ:CALA) opened at 17.75 on Wednesday. Calithera Biosciences, Inc. has a 52 week low of $2.20 and a 52 week high of $20.05. The firm has a 50-day moving average price of $16.15 and a 200-day moving average price of $14.69. The stock’s market cap is $629.70 million.
Calithera Biosciences (NASDAQ:CALA) last announced its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.15) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.29) by $0.14. The business had revenue of $7.26 million for the quarter, compared to analysts’ expectations of $4.80 million. On average, equities research analysts predict that Calithera Biosciences, Inc. will post ($0.81) EPS for the current year.
In other Calithera Biosciences news, major shareholder Adage Capital Partners Gp, L.L sold 576,000 shares of the stock in a transaction that occurred on Thursday, September 28th. The shares were sold at an average price of $15.64, for a total value of $9,008,640.00. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 16.30% of the company’s stock.
A number of research analysts recently issued reports on CALA shares. Zacks Investment Research upgraded Calithera Biosciences from a “hold” rating to a “strong-buy” rating and set a $21.00 price objective for the company in a research report on Tuesday, July 11th. William Blair assumed coverage on Calithera Biosciences in a research note on Thursday, October 5th. They set an “outperform” rating on the stock. Finally, BidaskClub downgraded Calithera Biosciences from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 12th. One analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the stock. Calithera Biosciences currently has a consensus rating of “Buy” and an average target price of $15.50.
About Calithera Biosciences
Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.
Receive News & Ratings for Calithera Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences Inc. and related companies with our FREE daily email newsletter.